ANN ARBOR, Mich., May 27, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Ronnda Bartel, Ph.D., chief scientific officer, will participate in a plenary session at the first annual Stem Cell Investor & Executive Networking Conference Event (SCIENCE). In the session, entitled "Autologous Approaches," Dr. Bartel will present an update on novel technology for cardiovascular regeneration with cellular therapies produced from a small sample of a patient's own bone marrow. This plenary session will take place from 2:00 p.m. to 2:45 p.m. To join the conference via webcast, please register at https://www1.gotomeeting.com/register/134153232">https://www1.gotomeeting.com/register/134153232. If you are unable to join via Internet, please call (800) 882-3610 and enter 2178545 when prompted for a passcode. If you are calling from outside the U.S., please use the international phone number (412) 380-2000.
Hosted by National Securities and MD Becker Partners, the SCIENCE program unites investors and industry executives to exchange information and highlight opportunities in the expanding stem cell industry. The event brings together researchers, clinicians, business leaders, key investors, and other stakeholders to offer presentations, share information, and discuss the future of the field.
SCIENCE will take place on June 1, 2010, from 11:00 a.m. to 4:00 p.m. at 120 Broadway, second floor, in New York City. Additional information and registration details are available at www.mdbpartners.com/science.
About Aastrom Biosciences
Aastrom Biosciences is developing autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies using a patient's own bone marrow that can be delivered directly to damaged tissues. Aastrom has advanced this technology into late-stage clinical development and is conducting two Phase 2 clinical trials to treat dilated cardiomyopathy and a Phase 2b clinical trial to treat critical limb ischemia. For more information, please visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including without limitation, statements concerning clinical trial plans, objectives and expectations, clinical activity timing, intended product development, disease treatment and progression, patient symptoms and responses to treatment, treatment options and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.